News Releases

News Releases

October 5, 2020
CAMBRIDGE, Mass. , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Phillip Samayoa , vice president of strategy and portfolio development, will present a company
August 5, 2020
CAMBRIDGE, Mass. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today announced that management will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, Aug.
June 16, 2020
CAMBRIDGE, Mass. , June 16, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the closing of its initial public offering of 12,105,263 shares of its common stock at an initial public offering
June 11, 2020
CAMBRIDGE, Mass. , June 11, 2020 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of gene therapy, today announced the pricing of its initial public offering of 10,526,316 shares of its common stock at an initial public offering
March 30, 2020
CAMBRIDGE, Mass. and SAN FRANCISCO, March 30, 2020 –  Generation Bio  and  Vir Biotechnology   (Nasdaq: VIR)  today announced a collaborative research agreement to explore the potential for Generation Bio’s non-viral gene therapy platform to extend the impact and reach of Vir’s current or future
January 10, 2020
CAMBRIDGE, Mass., Jan. 10, 2020 –  Generation Bio , a company leading a new generation of gene therapy, today announced the company will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2020. President and Chief Executive Officer Geoff McDonough,
cross